| 1 |
34783141 | A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells. | 2022 Mar 1 |
6 |
| 2 |
30884449 | Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation. | 2019 Jun |
4 |
| 3 |
29180522 | Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. | 2018 Feb |
1 |
| 4 |
28025084 | A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. | 2017 Mar |
1 |
| 5 |
29297305 | Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection. | 2017 Dec 28 |
1 |
| 6 |
26153443 | Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. | 2016 |
2 |
| 7 |
24704773 | The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. | 2015 |
1 |
| 8 |
24943406 | Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. | 2015 Feb |
2 |
| 9 |
23274664 | Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. | 2013 Mar |
1 |
| 10 |
23504694 | Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. | 2013 Sep |
1 |
| 11 |
22508297 | Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. | 2012 Jul |
5 |